Kleodina (Ethinylestradiol, Levonorgestrel)

The ethinylestradiol component provides estrogenic activity, while levonorgestrel supplies progestogenic effects. Together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting LH and FSH release, which prevents ovulation. The progestin also thickens cervical mucus and alters the endometrium, creating an environment unsuitable for fertilisation and implantation.

The dosing regimen for Kleodina is determined by the prescribing healthcare professional. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but exact instructions must be provided by the prescriber.

Kleodina is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be stopped immediately. Regarding breastfeeding, clinicians should evaluate the risk‑benefit ratio, as hormonal contraceptives can affect milk production and infant exposure.

To order Kleodina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Kleodina contains the standard dose combination of ethinylestradiol and levonorgestrel, a widely used progestin. Compared with pills that use newer progestins, Kleodina offers a well‑characterised efficacy and safety profile, but individual tolerability may differ. Choice of formulation often depends on patient‑specific factors such as side‑effect sensitivity and drug‑interaction risk.

Kleodina tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct sunlight. Keep out of reach of children and do not use after the expiration date printed on the label.

Kleodina is taken orally, usually as a single tablet each day at the same time. A typical cycle consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their prescriber.

The most serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rarely, severe allergic reactions or hepatic adenomas may occur. Patients should seek immediate medical attention if they experience unexplained leg pain, chest discomfort, severe headache, or signs of an allergic reaction.

Kleodina is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking medications that significantly reduce its effectiveness.